Elevating CDCA3 levels in non-small cell lung cancer enhances sensitivity to platinum-based chemotherapy
Katrina Kildey(Translational Research Institute), Mark N. Adams(Queensland University of Technology)
Cited by 26
Related Papers
Expression of CDCA3 Is a Prognostic Biomarker and Potential Therapeutic Target in Non–Small Cell Lung Cancer
|Journal of Thoracic Oncology|2017|84
The Role of Palmitoylation in Signalling, Cellular Trafficking and Plasma Membrane Localization of Protease-Activated Receptor-2
|PLoS ONE|2011|52
hSSB1 (NABP2/OBFC2B) modulates the DNA damage and androgen‐induced transcriptional response in prostate cancer
|The Prostate|2023|13
Elevating CDCA3 Levels Enhances Tyrosine Kinase Inhibitor Sensitivity in TKI-Resistant EGFR Mutant Non-Small-Cell Lung Cancer
|Cancers|2021|11
Inhibition of Aurora B kinase (AURKB) enhances the effectiveness of 5-fluorouracil chemotherapy against colorectal cancer cells
|British Journal of Cancer|2024|11